A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
← catalyst calendarNCT04414475 · readout ≤ 529 d
Sponsored by Karyopharm Therapeutics Inc (industry) · KPTI — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
127estimated
Sites
16
Countries
Greece, Israel
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-01 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2020-06-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma, Refractory
Interventions
- Drug: Selinexor — also filed as KPT-330, XPOVIO
- Drug: Dexamethasone — also filed as Decadron
- Drug: Bortezomib — also filed as Velcade
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR)
measured From the date of randomization up to death (approximately 60 months)
Publications
- PMID 38826786 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · KPTI's whole pipeline · Catalyst calendar · Every registered study · What changed